

Contents

<i>Contributors</i>	<i>vii</i>
<i>Preface</i>	<i>ix</i>
<i>Acknowledgements</i>	<i>xvi</i>
Part 1 Screening	
1 CT-based screening for lung cancer: philosophy, study designs and current trials <i>Janet E Husband and Nicholas Wald</i>	3
Part 2 Surgical intervention	
2 Downstaging disease before surgery: a review of current strategies <i>Peter Goldstraw</i>	15
3 Extended resection and reconstructive surgery: a review of current strategies <i>Francis Wells</i>	23
Part 3 Medical intervention	
4 CHART, CHARTWEL and combined modalities: evidence for clinical effectiveness and the consequences of under-utilization <i>Michele I Saunders</i>	31
5 Scientific evidence and expert clinical opinion for medical intervention in early non-small cell lung cancer <i>Sarah Khan and Penella J Woll</i>	41
6 An update of the evidence on chemotherapy in advanced or metastatic non-small cell lung cancer <i>David Gibbs, Mary O'Brien and Andreas Polychronis</i>	61
Part 4 Clinical trials and novel therapies	
7 Generating new medical evidence for management: an overview of clinical trials in progress <i>Jeremy PC Steele and Robin M Rudd</i>	83
8 Biological approaches to the management of lung cancer: the theoretical basis and clinical significance of novel therapies targeting the epidermal growth factor receptor <i>Malcolm Ranson, G Jayson and N Thatcher</i>	93

Part 5 Clinical governance

9	Guidance on the management of lung cancer issued by NICE and the demand for chemotherapy in non-small cell lung cancer <i>Michael Cullen</i>	107
10	Developing lung cancer services: the impact of modernization of the NHS <i>RJ Fergusson and Anna Gregor</i>	113
11	The impact of lung cancer patient groups on the delivery of the clinical service <i>Jesme Baird</i>	119
12	Auditing the quality of lung cancer services: towards formal accreditation and appraisal of clinical services <i>DR Baldwin</i>	127
	<i>Index</i>	<i>141</i>

- PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from nine randomised trials. *The Lancet* **352**: 257–263.
- Rose PG, Bundy BN, Watkins EB et al. (1999) Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. *New England Journal of Medicine* **340**: 1144–1153.
- Rosell R (1999) New approaches in the adjuvant and neoadjuvant therapy of NSCLC, including docetaxel (Taxotere) combinations. *Seminars in Oncology* **26**(suppl 11): 32–37.
- Rosell R, Gomez-Codina J, Camps C et al. (1994) A Randomised trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. *New England Journal of Medicine* **330**: 153–158.
- Rosell R, Gomez-Codina J, Camps C et al. (1999) Preresectional chemotherapy in stage IIIA non-small cell lung cancer: a 7-year assessment of a randomized controlled trial. *Lung Cancer* **47**: 7–14.
- Roth JA, Fosella F, Komaki P et al. (1994) A randomised trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA NSCLC. *Journal of the National Cancer Institute* **86**: 673–680.
- Roth JA, Atkinson EN, Fosella F et al. (1998) Long term follow up of patients enrolled in a randomised trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non small cell lung cancer. *Lung Cancer* **21**: 1–6.
- Rowell NP, Williams CJ (2001) Radical radiotherapy for stage I/II NSCLC in patients not sufficiently fit for or declining surgery (medically inoperable) (Cochrane Review). The Cochrane Library, Issue 3, Oxford.
- Royal College of Radiologists' Clinical Information Network (1999) Guidelines on the non-surgical management of lung cancer. *Clinical Oncology* **11**: S23–S28.
- Saunders M, Dische S, Barrett A et al. on behalf of the CHART Steering Committee (1999) Continuous hyperfractionated accelerated radiotherapy versus conventional radiotherapy in NSCLC: mature data from the randomised multi-centre trial. *Radiotherapeutic Oncology* **52**: 137–148.
- Sause W, Scott C, Taylor S et al. (1995) RTOG 88–08, ECOG 4588, preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. *Journal of the National Cancer Institute* **87**: 189–205.
- Sause W, Kolesar P, Taylor S et al. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. *Chest* **117**: 358–64.
- Schaake-Koning C, van den Bogaert W, Dalesio O et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. *New England Journal of Medicine* **326**: 524–30.
- Sculier JP, Paesmans M, Lafitte JJ et al. (1999) A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. *Annals in Oncology* **10**: 295–303.
- Shepherd FA (1997) Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. *Lung Cancer* **17**(suppl 1): S121–S136.
- Siegenthaler MP, Pisters KM, Merriman KW et al. (2001) Preoperative chemotherapy does not increase surgical morbidity. *Annals of Thoracic Surgery* **71**: 1105–1112.

Table 6.6 Trials comparing chemotherapy doublets and triplets

<i>Regimen</i>	<i>Number</i>	<i>Response rate (%)</i>	<i>Median survival (weeks)</i>	<i>Reference</i>
Carboplatin–paclitaxel	71	28	33	Hussein et al. (2000)
Carboplatin–paclitaxel–gemcitabine		61	45	
Mitomycin–ifosfamide–cisplatin	179	37	46	Depierre et al. (2001)
Mitomycin–ifosfamide–cisplatin → vinorelbine		37	55	
Cisplatin–gemcitabine–vinorelbine	180	47	51	Comella et al. (2000)
Gemcitabine–cisplatin		37	42	
Vinorelbine–cisplatin		25	35	
Carboplatin–gemcitabine → paclitaxel	204	21	36	Edelman et al. (2001)
Carboplatin–vinorelbine → docetaxel		28	36	
Mitomycin–vinblastine–cisplatin or Mitomycin–ifosfamide–cisplatin	232	33	N/A	Danson et al. (2001)
Gemcitabine–cisplatin		39		
Carboplatin–paclitaxel–gemcitabine	243	34	44	Thompson et al. (2001)
Carboplatin–paclitaxel–vinorelbine		42	21	
Paclitaxel–gemcitabine		29	33	
Paclitaxel–vinorelbine		29	30	
Mitomycin–vinblastine–cisplatin	247	41	17	Gebbia et al. (2002)
Vinorelbine–cisplatin		38	18	
Mitomycin–vinblastine–cisplatin	248	27	27	Melo et al. (2002)
Vinorelbine–cisplatin		37	38	
Gemcitabine–cisplatin		48	41	
Mitomycin–ifosfamide–cisplatin	307	26	41	Crino et al. (1999)
Gemcitabine–cisplatin		38	37	
Cisplatin–gemcitabine–vinorelbine	343	44	51	Comella (2001)
Cisplatin–gemcitabine		28	38	
Cisplatin–gemcitabine–paclitaxel		48	51	
Gemcitabine–cisplatin	562	41	41	Alberola et al. (2001)
Gemcitabine–cisplatin–vinorelbine		40	34	
Gemcitabine–vinorelbine → Ifosfamide–vinorelbine		24	45	

Figures in bold face indicate a significant ($p < 0.05$) difference between groups, N/A: not available. Arrows indicate sequential administration.

Non-platinum combination chemotherapy with third-generation agents

The growing evidence for the equal efficacy of third-generation agents and platinum have led to trials of non-platinum-containing combination therapy. A trial comparing

- Rodriguez J, Pawel J, Pluzanska A et al. (2001) A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. *Proceedings of the American Society of Clinical Oncology* **20**: abstract 1252.
- Rosso R, Ardizzoni A, Salvari F et al. (1988) Etoposide v etoposide and cisplatin in the treatment of advanced non-small cell lung cancer: a FONICAP randomized study. *Seminars in Oncology* **15**(6 suppl 7): 49–51.
- Roszkowski K, Pluzanska A, Krzakowski M et al. (2000) A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) *Lung Cancer* **27**: 145–157.
- Sandler AB, Nemunaitis J, Denham C et al. (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. *Journal of Clinical Oncology* **18**: 122–130.
- Scagliotti GV, De Marinis F, Rinaldi M et al. (2001) Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. *Proceedings of the American Society of Clinical Oncology* **20**: abstract 1227.
- Schiller JH, Harrington D, Belani CP et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *New England Journal of Medicine* **346**(2): 92–98.
- Sederholm CJMF (2002) A phase III study in advanced non-small cell lung cancer (NSCLC) comparing gemcitabine (G) with gemcitabine in combination with carboplatin (C): Data from an ongoing study by the Swedish Lung Cancer Study Group (SLUSG). *Proceedings of the American Society of Clinical Oncology* **21**: abstract 1162.
- Shepherd FA, Dancey J, Ramlan R et al. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *Journal of Clinical Oncology* **18**: 2095–2103.
- Smith IE, O'Brien ME, Talbot DC et al. (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. *Journal of Clinical Oncology* **19**: 1336–1343.
- Socinski MA, Schell MJ, Peterman A et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV NSCLC. *Journal of Clinical Oncology* **20**(5): 1335–1345.
- Splinter TA, Sahnoud T, Festen J et al. (1996) Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. *Journal of Clinical Oncology* **14**: 127–134.
- Takeda, K, N. Yamamoto, Negoro S et al. (2000) Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small-cell lung cancer (NSCLC); A West Japan Thoracic Oncology Group (WJTOG) Study. *Proceedings of the American Society of Clinical Oncology* **19**: abstract 1944.
- Talbot D, White S, Jones P et al. (2000) Phase II Study of exatecan mesylate (DX-8951f) in advanced NSCLC. *Proceedings of the American Society of Clinical Oncology* **19**: abstract 2166.
- ten Bokkel Huinink WW, Bergman B, Chemaissani A et al. (1999) Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. *Lung Cancer* **26**: 85–94.